NRBO: NeuroBo Pharmaceuticals, Inc. Total Debt to Capital

NeuroBo Pharmaceuticals (NRBO) management focuses on developing therapeutic agents to combat brain and cardiovascular pathologies. This chart illustrating the total debt-to-equity ratio captured a figure of 0.02. This is driven by a shortage of internal funds due to R&D expenditures, which forces the company to secure loans. The situation is further complicated by strict FDA oversight and patent protection within the metabolic drug sector.

Investors use this ratio to assess financial stability and the extent of the company's reliance on borrowed funds. This metric is calculated as the sum of all liabilities divided by equity, and the displayed debt-to-equity ratio is critically important for NeuroBo Pharmaceuticals (NRBO), whose liquidity determines the success of clinical trials for MASH drugs and partnerships with Dong-A ST.